FDA targeting anticompetitive generics practices

In a blog post Wednesday, FDA Commissioner Scott Gottlieb said the agency plans to spur generic drug competition by targeting anticompetitive practices. At a public meeting on July 18, Gottlieb said the agency would seek community input on how companies misuse FDA rules or otherwise act to impede development of and access to new generics.

The moves are part of the agency’s Drug Competition Action Plan, which aims to support generic competition and address soaring drug prices via expanded access to lower-cost generics...